

## Developing a bispecific siRNA therapy for dyslipidemia patients with complex symptoms(Csi103)

Curigin Co., Ltd.



METABOLIC	Candidate
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Patients with dyslipidemia who have a combination of high LDL-cholesterol and high triglycerides
Target	PCSK9 and APOC3
MoA(Mechanism of Action)	<ol style="list-style-type: none"> <li>1) A bispecific siRNA inhibits the gene expression of PCSK9 and APOC3 in hepatocytes</li> <li>2) It reduces the amount of LDL cholesterol in the blood by increasing the amount of LDLR on the surface of hepatocytes</li> <li>3) It activates lipoprotein lipase(LPL) in hepatocytes to promote triglyceride breakdown</li> </ol>
Competitiveness	<ol style="list-style-type: none"> <li>1) Increased therapeutic efficacy by simultaneously inhibiting two genes compared to single gene targeting competitors</li> <li>2) Expected to be effective in treating dyslipidemia with complex symptoms</li> <li>3) Low side effects(no off-target effects) and simultaneous modulation of two genes</li> </ol>
Development Stage	Candidate
Route of Administration	Subcutaneous injection, once per 6 months

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*